close
On the Record
5 mins to read

EpiPen, Spinraza funding leaves bitter-sweet heaviness

OPINION: Pharmac funding decisions come far too late for some.

NBR columnist Rachel Smalley speaks with Calida Stuart-Menteath

For more than quarter of a century, EpiPens have been on Pharmac’s waiting list. 

The adrenaline auto-injector provides a potentially life-saving treatment for people at risk of anaphylaxis with the mechanism of delivery just a quick shot of adrenalin injected automatically when the pen is pressed

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive offer for uni students studying at a New Zealand university (valued at $499).
Individual
Group membership
NBR Marketplace
NZ Aviation News

Yearly Premium Online Subscription

NZ$499.00 / yearly

Monthly Premium Online Subscription

NZ$44.95 / monthly

Smartphone Only Subscription

NZ$24.95 / monthly

Premium Group Membership 10 Users

NZ$350+GST / monthly

$35 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$600+GST / monthly

$30 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1250+GST / monthly

$25 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$1875+GST / monthly

$18.75 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$499.00 / yearly

Aviation News - Monthly

NZ$14.95 / monthly

Already have an account? Login
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
EpiPen, Spinraza funding leaves bitter-sweet heaviness
On the Record,
95957